KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Goodwill & Intangibles (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Goodwill & Intangibles data on record, last reported at $382.4 million in Q3 2025.

  • For Q3 2025, Goodwill & Intangibles changed N/A year-over-year to $382.4 million; the TTM value through Sep 2025 reached $382.4 million, changed N/A, while the annual FY2024 figure was $426.0 million, 160.94% up from the prior year.
  • Goodwill & Intangibles reached $382.4 million in Q3 2025 per PCRX's latest filing, down from $426.0 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $769.2 million in Q4 2021 and bottomed at $90.6 million in Q3 2021.
  • Average Goodwill & Intangibles over 5 years is $331.0 million, with a median of $192.1 million recorded in 2021.
  • Peak YoY movement for Goodwill & Intangibles: skyrocketed 292.3% in 2021, then crashed 76.81% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $769.2 million in 2021, then decreased by 8.5% to $703.8 million in 2022, then plummeted by 76.81% to $163.2 million in 2023, then soared by 160.94% to $426.0 million in 2024, then decreased by 10.23% to $382.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $382.4 million in Q3 2025, $426.0 million in Q4 2024, and $163.2 million in Q4 2023.